{
    "organizations": [],
    "uuid": "137bc545aba12ba5a01256bfb1d4a6d24587239c",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/04/25/pr-newswire-acelrx-to-announce-first-quarter-2018-results-and-provide-a-corporate-update-on-wednesday-may-9th-2018.html",
    "ord_in_thread": 0,
    "title": "AcelRx to announce first quarter 2018 results and provide a corporate update on Wednesday, May 9th, 2018",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "REDWOOD CITY, Calif., April 25, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company, today announced that it will release first quarter financial results after market close on Wednesday, May 9th, 2018. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on May 9th, 2018 to discuss the financial results and provide a corporate update.\nInvestors who wish to participate in the conference call may do so by dialing (866) 361-2335 for domestic callers, (855) 669-9657 for Canadian callers or (412) 902-4204 for international callers. Those interested in listening to the conference call live via the Internet may do so by visiting the Investors page of the company's website at www.acelrx.com and clicking on the webcast link on the Investors home page.\nA webcast replay will be available on the AcelRx website for 90 days following the call by visiting the Investor page of the company's website at www.acelrx.com .\nAbout AcelRx Pharmaceuticals, Inc.\nAcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised setting. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has two product candidates including DSUVIA™ (sufentanil sublingual tablet, 30 mcg), known as DZUVEO outside the United States, with a proposed indication for the treatment of moderate-to-severe acute pain in medically supervised settings, and ZALVISO® (sufentanil sublingual tablet system, SST system, 15 microgram) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings.\nFor additional information about AcelRx's clinical programs, please visit www.acelrx.com .\nView original content with multimedia: http://www.prnewswire.com/news-releases/acelrx-to-announce-first-quarter-2018-results-and-provide-a-corporate-update-on-wednesday-may-9th-2018-300636575.html\nSOURCE AcelRx Pharmaceuticals, Inc.",
    "published": "2018-04-26T00:30:00.000+03:00",
    "crawled": "2018-04-26T01:45:09.010+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "redwood",
        "city",
        "april",
        "acelrx",
        "pharmaceutical",
        "nasdaq",
        "acrx",
        "specialty",
        "pharmaceutical",
        "company",
        "today",
        "announced",
        "release",
        "first",
        "quarter",
        "financial",
        "result",
        "market",
        "close",
        "wednesday",
        "may",
        "9th",
        "acelrx",
        "management",
        "host",
        "conference",
        "call",
        "eastern",
        "time",
        "pacific",
        "time",
        "may",
        "9th",
        "discus",
        "financial",
        "result",
        "provide",
        "corporate",
        "update",
        "investor",
        "wish",
        "participate",
        "conference",
        "call",
        "may",
        "dialing",
        "domestic",
        "caller",
        "canadian",
        "caller",
        "international",
        "caller",
        "interested",
        "listening",
        "conference",
        "call",
        "live",
        "via",
        "internet",
        "may",
        "visiting",
        "investor",
        "page",
        "company",
        "website",
        "clicking",
        "webcast",
        "link",
        "investor",
        "home",
        "page",
        "webcast",
        "replay",
        "available",
        "acelrx",
        "website",
        "day",
        "following",
        "call",
        "visiting",
        "investor",
        "page",
        "company",
        "website",
        "acelrx",
        "pharmaceutical",
        "acelrx",
        "pharmaceutical",
        "specialty",
        "pharmaceutical",
        "company",
        "focused",
        "development",
        "commercialization",
        "innovative",
        "therapy",
        "use",
        "medically",
        "supervised",
        "setting",
        "acelrx",
        "proprietary",
        "sublingual",
        "formulation",
        "technology",
        "delivers",
        "sufentanil",
        "consistent",
        "pharmacokinetic",
        "profile",
        "company",
        "two",
        "product",
        "candidate",
        "including",
        "sufentanil",
        "sublingual",
        "tablet",
        "mcg",
        "known",
        "dzuveo",
        "outside",
        "united",
        "state",
        "proposed",
        "indication",
        "treatment",
        "acute",
        "pain",
        "medically",
        "supervised",
        "setting",
        "sufentanil",
        "sublingual",
        "tablet",
        "system",
        "sst",
        "system",
        "microgram",
        "developed",
        "innovatively",
        "designed",
        "analgesia",
        "pca",
        "system",
        "reduction",
        "acute",
        "pain",
        "medically",
        "supervised",
        "setting",
        "additional",
        "information",
        "acelrx",
        "clinical",
        "program",
        "please",
        "visit",
        "view",
        "original",
        "content",
        "multimedia",
        "http",
        "source",
        "acelrx",
        "pharmaceutical",
        "inc"
    ]
}